Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Heart monitoring breakthrough: 14 days vs. 24 hours for MVP patients

NCT ID NCT06378996

Knowledge-focused Sponsor: Universitaire Ziekenhuizen KU Leuven Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jul 22, 2026 · Updated 2 times

Summary

This study tests whether wearing a heart monitor for 14 days can detect dangerous heart rhythms in people with mitral valve prolapse (a common heart valve condition) better than the usual 24-hour test. About 60 adults with MVP will wear a patch monitor for two weeks. The goal is to see how often risky rhythms occur and how much they vary day-to-day, which could lead to better detection and future research.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

60 people

The number who actually took part.

Started

May 2024

Finished

Jun 2026

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Patients aged 18 years or older * Mitral valve prolapse diagnosed on previous echocardiography or cardiac MRI * New York Heart association classification ≥3 for cohort 3 and classification 1 or 2 for cohorts 1 and 2 * Willing and able to provide signed written informed consent * No contra-indication for long-term monitoring (known allergy to adhesives) Exclusion Criteria: * Prior cardiac surgery, including previous mitral valve intervention * Prior endovascular mitral valve repair (MitraClip) * Previous catheter ablation of ventricular arrhythmias * Patients not in sinus rhythm * Patients on anti-arrhythmic drugs but betablockers * Known alternative arrhythmic substrate, for example previous myocardial infarction * Known allergy to adhesives

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Mitral valve prolapse are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

cardiac rhythm disease mitral valve prolapse ventricular tachycardia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Mitral valve prolapse Ventricular arrythmia

Contacts and locations

Locations

  • UZ Leuven

    Leuven, Vlaams-Brabant, 3000, Belgium

More trials for these conditions

Other studies related to the condition(s) this trial covers.